News
May 6, 2025
Almac Discovery and Formosa Pharmaceuticals announce global licensing agreement for development and commercialisation of ALM-401, a first-in-class EGFRxROR1 Bispecific Antibody-Drug Conjugate
News
May 30, 2024
Almac Discovery nominates ALM-401 as a First in Class Bispecific Next Generation ADC targeting EGFR/ROR1 to progress into pre-clinical development
News
November 29, 2023
Almac Discovery and Queen’s University launch state-of-the-art Chemoproteomics facility in Belfast
News
June 6, 2023
WEE1 Inhibitor discovered by Almac Discovery advanced into two clinical studies addressing the treatment of advanced solid tumours